Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 3/20 | 0.63 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.63 |
| ▸ | CTSK | P43235 | 9/20 | 0.62 |
| ▸ | CTSS | P25774 | 4/20 | 0.59 |
| ▸ | CTSL | P07711 | 3/20 | 0.59 |
| ▸ | CTSB | P07858 | 1/20 | 0.59 |
| ▸ | CA5A | P35218 | 1/20 | 0.58 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.56 |
| ▸ | NPY4R | P50391 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035561 | 0.98 | CAPN1 (0.63) | CAPN1CAPN2CTSKCTSSCTSL | |
| SCHEMBL10787733 | 0.92 | NPY4R (0.61) | CAPN1CAPN2CTSLCTSBNPY1R | |
| SCHEMBL10787739 | 0.92 | NPY4R (0.61) | CAPN1CAPN2CTSLCTSBNPY1R | |
| SCHEMBL11144460 | 0.89 | PSMB1 (0.58) | CAPN1CTSLCTSBHTRA1NPY1R | |
| Hydrochloric Acid SCHEMBL11141349 | 0.88 | PSMB1 (0.57) | CAPN1CTSLCTSBHTRA1NPY1R | |
| SCHEMBL10784684 | 0.88 | CAPN1 (0.61) | CAPN1CAPN2CTSKCTSSCTSL | |
| SCHEMBL10784713 | 0.88 | CAPN1 (0.61) | CAPN1CAPN2CTSKCTSSCTSL | |
| SCHEMBL20827908 | 0.87 | CAPN1 (0.66) | CAPN1CTSLNPY1RNPY4R | |
| SCHEMBL20827885 | 0.87 | CAPN1 (0.66) | CAPN1CTSLNPY1RNPY4R | |
| SCHEMBL9115066 | 0.87 | CAPN1 (0.80) | CAPN1CAPN2CTSKCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169289-B2 | Peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation | STRONGBONE AB (SE) | 2015-10-27 | — | — | US | disclosed |
| US-20140243274-A1 | NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION | STRONGBONE AB (SE) | 2014-08-28 | — | — | US | disclosed |
| US-8748370-B2 | Peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation | STRONGBONE AB (SE) | 2014-06-10 | — | — | US | disclosed |
| US-20120108515-A1 | NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION | NEOBIOTICS AB (SE) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108515-A1 | NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION | BMP2, SOST, BMP1 | CAPN1 1948/4885CAPN2 1886/4885CTSK 52/4885 |
| US-20140243274-A1 | NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION | BMP2, CALCRL, ARG1 | CAPN1 2260/4885CAPN2 2212/4885CTSK 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.